| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | STE | Ordinary Shares | Award | +160 | +0.46% | 35K | Jun 2, 2021 | Direct | F1 | ||
| holding | STE | Ordinary Shares | 27.2K | Jun 2, 2021 | See Footnotes Below | F2, F3 |
| Id | Content |
|---|---|
| F1 | Received in exchange for 475 shares of Cantel Medical Corp. ("Cantel") common stock in connection with the acquisition of Cantel by STERIS plc ("STERIS") pursuant to a series of transactions ("Mergers"). Holders of Cantel common stock received $16.93 in cash and 0.33787 STERIS ordinary shares per Cantel share outstanding immediately prior to the Mergers. |
| F2 | Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC is in turn the general partner of Breeden Partners L.P. (the "Fund"). |
| F3 | Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. |